Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 24, 2017

Primary Completion Date

January 1, 2019

Study Completion Date

October 20, 2021

Conditions

Salivary Gland CarcinomaMetastatic CancerRecurrent Cancer

Interventions

DRUG

Nivolumab

3 mg/kg, every two weeks, during a maximum of one year

Trial Locations (11)

Centre Georges François Leclerc, Dijon

CHU Bordeaux, Bordeaux

ICM Val d'Aurelle, Montpellier

Centre René Gauducheau, Saint-Herblain

Institut de cancérologie Alexis Vautrin, Vandœuvre-lès-Nancy

Centre Paul Strauss, Strasbourg

Centre Léon Bérard, Lyon

Institut Curie Saint Cloud, Saint-Cloud

Gustave Roussy, Villejuif

Centre Antoine Lacassagne, Nice

Institut Curie, Paris

All Listed Sponsors

lead

UNICANCER

OTHER

NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter